Posted by Michael Wonder on 27 Dec 2023
Imaging Biometrics granted FDA fast track
19 December 2023 - Imaging Biometrics is pleased to announce that the US FDA has granted fast track designation for oral gallium maltolate, IB’s therapeutic for the treatment of adult patients with relapsed or refractory glioblastoma, IDH wild type.
Receiving both fast track and orphan drug designations from the FDA for oral gallium maltolate validates the importance of advancing the development of this treatment for these patients.
